Page 35 - Read Online

Page 14 of 16 Merhi et al. J Cancer Metastasis Treat 2021;7:42 https://dx.doi.org/10.20517/2394-4722.2021.80

inflammatory signaling, ROS generation and proton dynamics. Antioxidants (Basel) 2020;10:18. DOI PubMed PMC
23. Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St John’s wort (Hypericum perforatum L.)
extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human
malignant cell lines. Eur J Pharm Biopharm 2003;56:121-32. DOI PubMed
24. Quiney C, Billard C, Faussat AM, et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic
lymphocytic leukemia. Leukemia 2006;20:491-7. DOI PubMed
25. Liu JY, Liu Z, Wang DM, et al. Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a
mitochondrial-related pathway. Chem Biol Interact 2011;190:91-101. DOI PubMed
26. Merhi F, Tang R, Piedfer M, et al. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad
and Noxa activation in human myeloid tumor cells. PLoS One 2011;6:e25963. DOI PubMed PMC
27. Liu YC, Lin KH, Hsieh JH, et al. Hyperforin Induces apoptosis through extrinsic/intrinsic pathways and inhibits NF-ĸB-modulated
survival and invasion potential in bladder cancer. In Vivo 2019;33:1865-77. DOI PubMed PMC
28. Billard C, Merhi F, Bauvois B. Mechanistic insights into the antileukemic activity of hyperforin. Curr Cancer Drug Targets
2013;13:1-10. PubMed
29. Lorusso G, Vannini N, Sogno I, et al. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer
2009;45:1474-84. DOI PubMed
30. Rothley M, Schmid A, Thiele W, et al. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress
tumor-induced lymphangiogenesis in vivo. Int J Cancer 2009;125:34-42. DOI PubMed
31. Dell’Aica I, Caniato R, Biggin S, Garbisa S. Matrix proteases, green tea, and St. John’s wort: biomedical research catches up with
folk medicine. Clin Chim Acta 2007;381:69-77. DOI PubMed
32. Quiney C, Billard C, Mirshahi P, Fourneron JD, Kolb JP. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule
formation by endothelial cells. Leukemia 2006;20:583-9. DOI PubMed
33. Allegra A, Tonacci A, Spagnolo EV, Musolino C, Gangemi S. Antiproliferative effects of St. John’s Wort, its derivatives, and other
hypericum species in hematologic malignancies. Int J Mol Sci 2020:22. DOI PubMed PMC
34. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176-85.
DOI PubMed
35. Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N. VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol
Hematol 2011;80:241-56. DOI PubMed
36. Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination
therapies. Leukemia 2021;35:299-311. DOI PubMed
37. Cucchi DGJ, Polak TB, Ossenkoppele GJ, et al. Two decades of targeted therapies in acute myeloid leukemia. Leukemia
2021;35:651-60. DOI PubMed
38. Estey E. New treatments for acute myeloid leukemia: how much has changed? Leukemia 2021;35:45-6. DOI PubMed
39. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood
2000;95:309-13. PubMed
40. Padró T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR
(VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10. DOI PubMed
41. Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid
leukemia. Blood 1997;89:1870-5. PubMed
42. Ghannadan M, Wimazal F, Simonitsch I, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute
myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol 2003;119:663-71. DOI PubMed
43. Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA. Vascular endothelial growth factor secretion is an independent
prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002;8:2856-61. PubMed
44. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood
2000;96:2240-5. PubMed
45. Janowska-Wieczorek A, Marquez LA, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of
metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J
Haematol 1999;105:402-11. PubMed
46. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from
normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res
1999;5:1115-24. PubMed
47. Chaudhary AK, Chaudhary S, Ghosh K, Shanmukaiah C, Nadkarni AH. Secretion and expression of matrix metalloproteinase-2 and 9
from bone marrow mononuclear cells in myelodysplastic syndrome and acute myeloid leukemia. Asian Pac J Cancer Prev
2016;17:1519-29. DOI PubMed
48. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O. Primary human acute myelogenous leukemia cells release
matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol 2009;84:239-51. DOI
PubMed
49. King ME, Rowe JM. Recent developments in acute myelogenous leukemia therapy. Oncologist 2007;12 Suppl 2:14-21. DOI
PubMed
50. Bauvois B, Nguyen J, Tang R, Billard C, Kolb JP. Types I and II interferons upregulate the costimulatory CD80 molecule in
monocytes via interferon regulatory factor-1. Biochem Pharmacol 2009;78:514-22. DOI PubMed